FLOW trial: Sulthiame produced dose-dependent 16–35% AHI reductions — a pharmacologic option for CPAP‑intolerant OSA patients
Sulthiame, an oral carbonic anhydrase inhibitor, cut apnea events in the FLOW Phase 2 trial by roughly 16–35% depending on…
Sulthiame, an oral carbonic anhydrase inhibitor, cut apnea events in the FLOW Phase 2 trial by roughly 16–35% depending on…